X0306 4 2021-02-01 0 0001652130 Intellia Therapeutics, Inc. NTLA 0001671870 Rivera Jose E C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET; SUITE 130 CAMBRIDGE MA 02139 0 1 0 0 EVP, General Counsel Common Stock 2021-02-01 4 M 0 66000 6.83 A 120068 D Common Stock 2021-02-01 4 S 0 10476 63.31 D 109592 D Common Stock 2021-02-01 4 S 0 15594 64.11 D 93998 D Common Stock 2021-02-01 4 S 0 5312 65.01 D 88686 D Common Stock 2021-02-01 4 M 0 33000 13.88 A 121686 D Common Stock 2021-02-01 4 S 0 6617 63.34 D 115069 D Common Stock 2021-02-01 4 S 0 8366 64.16 D 106703 D Common Stock 2021-02-01 4 S 0 2827 65.05 D 103876 D Common Stock 2021-02-01 4 M 0 10000 14.58 A 113876 D Common Stock 2021-02-01 4 S 0 2326 63.44 D 111550 D Common Stock 2021-02-01 4 S 0 2386 64.18 D 109164 D Common Stock 2021-02-01 4 S 0 755 65.07 D 108409 D Common Stock 262210 I See Footnote Stock Option (right to buy) 6.83 2021-02-01 4 M 0 66000 0.00 D 2026-02-02 Common Stock 66000 39117 D Stock Option (right to buy) 13.88 2021-02-01 4 M 0 33000 0.00 D 2027-01-05 Common Stock 33000 72000 D Stock Option (right to buy) 14.58 2021-02-01 4 M 0 10000 0.00 D 2028-12-17 Common Stock 10000 61000 D The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.69 to $63.685, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.69 to $64.65, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.72 to $65.40, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.74 to $63.71, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.75 to $64.72, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.76 to $65.56, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.81 to $63.71, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.83 to $64.795, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.94 to $65.34, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price. Shares are held by Rivak Capital LLC ("Rivak"). Mr. Rivera is a member and the general manager of Rivak and has voting and dispositive power over these shares. The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on February 3, 2020. The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on January 6, 2021. The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 36,979 shares as of February 1, 2021. /s/Jose Rivera 2021-02-03